Defence Therapeutics Inc. (CSE:DTC)
Canada · Delayed Price · Currency is CAD 0.5000
+0.0500 (11.11%)
May 21, 2026, 3:37 PM EST
Defence Therapeutics Company Description
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases.
Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers.
The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020.
Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Defence Therapeutics Inc.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Sebastien Plouffe |
Contact Details
Address: 7171 Rue Frederick-Banting Montreal, QC QC Canada | |
| Phone | 514 947 2272 |
Stock Details
| Ticker Symbol | DTC |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | CAD |
| ISIN Number | CA24463V1013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sebastien Plouffe | Chief Executive Officer, President and Director |
| Arnab Kumar De A.C.M.A., C.M.A., C.P.A., CGMA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Mark Lambermon Ph.D. | Head of Quality and Operations |
| Dr. Maxime Parisotto | Chief Scientific Officer |